The “Cancer Hunter” That’s Disrupting Big Pharma and Unlocking Massive Profit Potential for Early Investors.

A $246 Billion Crisis: Cancer costs are exploding—creating one of the biggest profit waves in modern medicine.
The Warp Speed Revolution: New fast-track rules are accelerating breakthrough therapies from lab to market faster than ever before.
The Hidden Contender: A tiny, overlooked biotech may have built the “Cancer Hunter” poised to ride this surge to massive upside potential.

By Jason Williams, Guest Contributor & Editor, Future Giants

Friday, December 5, 2025 9:00 A.M. CDT · 10 min read

When Operation Warp Speed was launched on May 15, 2020, most people thought it was only about vaccines … and most investors only had eyes for Moderna.

It wasn’t a bad play at the time — the stock surged 645% in just twelve months after its Warp Speed debut.

Moderna was one of Operation Warp Speed’s biggest success stories. Image Source: Barchart.com

Other big winners included BioNTech, Pfizer’s little-known partner at the time, which surged nearly 266%.

Investors in BioNTech saw impressive growth in only 12 months. Image Source: Barchart.com

Even Novavax, a company many had written off, soared an astonishing 4,149% between February 2020 and February 2021.

Novavax’s 41x growth is one of this decade’s most astounding success stories. Image Source: Barchart.com

But what most investors missed was the bigger story: Washington proved we could move life-saving science from concept to clinic in record time … and it changed the entire playbook to make it happen.

By permanently tearing down bureaucratic red tape, Operation Warp Speed rewired how America handles breakthrough therapies.

Regulators now have the tools and precedent to fast-track treatments far beyond vaccines — into oncology, autoimmune disease, and more.

Companies are using Warp Speed’s playbook to build serious platforms in cancer and autoimmune disease.

And it can’t come soon enough.

Despite advances in medicine, cancer remains the second leading cause of death worldwide.

According to the World Health Organization’s most recent data, approximately 20 million new cancer cases were diagnosed globally in 2022, and nearly 10 million people died from the disease that same year.

That’s the equivalent of losing the entire population of Sweden every year, yet modern medicine is still struggling to turn the tide.

And with global cancer cases projected to rise to over 30 million annually by 2040, the need for a safer, more effective solution has never been more urgent.

Fortunately, thanks to Operation Warp Speed, biotech firms — including a little-known company I’ll tell you about in a moment — have spent these last few years running quieter, faster studies under the new fast-track pathways.

Those programs are now approaching readouts and partnership decisions.

Meanwhile, Wall Street’s goldfish-level attention span had wandered back to AI … leaving biotech underowned just as the seeds sown by Operation Warp Speed start to bear fruit.

I regularly tell my subscribers that the gap between attention and progress is the sweet spot for investors.

And that’s where I’ve discovered what I believe could be the biggest biotech opportunity available to investors today.

Introducing BioTech Investing Expert Jason Williams

My name’s Jason Williams.

I’m an investing expert whose research and analysis has been featured in Forbes. Fox Business. The Street. Even Investopedia.

I started my career on Wall Street working with Morgan Stanley, using my insights and analysis to help the ultra-wealthy build even more wealth.

But that wasn’t the life I wanted for myself … so I walked away.

I decided to use my skills to help everyday Americans — regular folks — people like you and me — who were always left out of the big money plays.

Now, I run one of the top investment newsletters in the country.

It’s called Future Giants, and it was built to help everyday investors access opportunities most people never hear about until it’s too late.

Tens of thousands of readers follow my research — not because I chase hype, but because I dig deep to uncover real, overlooked companies with explosive potential.

Across my newsletters, subscribers have seen opportunities for incredible gains on public market recommendations, including:

+1,037% increase Innovative Industrial Properties

+1,168% increase SoundHound AI

+3,399% increase Super Micro Computer

+4,016% increase NVIDIA

But here’s what most people don’t know about me…

Before I launched Future Giants, I was part of the IPO machine on Wall Street. I worked at Morgan Stanley during a historic wave of billion-dollar tech IPOs — including Fortinet, LinkedIn, and Facebook.

I saw how early insiders, venture funds, and connected elites were able to buy into these companies before the public ever got a chance.

I saw fortunes created — and regular investors left behind.

Future Giants is my answer to that.

Through this private investing research service, I help regular folks discover high-potential, early-stage opportunities — including rare deals that most investors never hear about until the big money’s already been made.

And today, I believe this revolutionary “Cancer Hunter” company could be one of those breakout opportunities.

It checks every box I look for in a potential winner.

And with Future Giants, I’ll show you exactly how to stake your claim in this company … before Wall Street catches on.

But before I do a deep dive into that company, I want to share some information you need to know about biotech investing, as well as five powerful reasons why my analysis reveals that this company could provide early investors with the potential for significant gains.

This little-known company that has developed what it calls a “Cancer Hunter” — a revolutionary therapy engineered to:

Transform the body’s Natural Killer (NK) cells into cancer-fighting superweapons
Target multiple cancers types from a single platform
Cut treatment costs by potentially more than 80%The company’s first-generation molecule achieved a 63.7% reduction in bone marrow blast levels. And the only reported side effect was a mild fever (easily treated with Tylenol).

The company’s first-generation molecule reduced cancer burden by an astonishing 63.7% — with no reported side effects — and the company’s second-gen molecule started clinical trials earlier this year.

In my opinion, that valuation looks like a launchpad to massive upside potential.

Because when breakthroughs like the “Cancer Hunter” hit paydirt, Big Pharma has a history of paying up. For example:

Gilead bought Kite for $11.9 billion
Celgene bought Juno for $9 billion
Pfizer paid $43 billion for Seagen

In a moment, I’ll reveal the ticker why I believe all investors should start their due diligence on this NASDAQ-listed company immediately.

But before I introduce you to my number-one subscriber pick in the underappreciated biotech sector, you need to understand more about the backdrop that makes setups like this so urgent.

How the “Silver Tsunami” Could Trigger a $246 Billion Healthcare Crisis

This company’s radical new medical platform is quietly preparing to do what no blockbuster drug or therapy ever has before.

Not treat a single cancer … but potentially identify and target them all.

And if you’re positioned early, this small firm’s breakthrough could hand you a once-in-a-generation windfall.

Let me explain.

A brutal economic reckoning is coming, but it’s not being caused by inflation, interest rates, or another real estate crash.

It’s coming from inside America’s most expensive system: healthcare.

Specifically, a tidal wave of cancer cases about to slam into Medicare, hospitals, insurers … and, most importantly, your wallet.

In 2022, there were 20 million new cancer cases worldwide. But by 2050, that number could nearly double, hitting 35 million, according to the World Health Organization.

In the U.S. alone, the aging Baby Boomer population is stepping straight into the blast zone.

By 2030, one in every five Americans will be over 65. That’s nearly 75 million people — a demographic where cancer risk spikes exponentially.

And with cancer incidence exploding, so is the cost…

“Cancer spending in the U.S. is projected to reach $246 billion by 2030…”

– American Association for Cancer Research

According to the American Association for Cancer Research, cancer spending is projected to reach $246 billion by 2030.

That’s a 30%+ surge from 2015 levels… and it’s threatening to bankrupt families and government programs alike.

Some healthcare experts are calling it a “financial toxicity” crisis.

And with more people getting sick, living longer, and surviving thanks to costly treatments … the system is strained to its breaking point.

But, as I’ve been telling my subscribers, this looming crisis isn’t just a tragedy; it’s also a transformational opportunity for early investors who know where to look.

The Breakthrough Immune Therapy That Could Lead to the Next Billion-Dollar Breakout

Because here’s what’s shocking…

Despite billions spent, most “next-gen” cancer advances still act like one-offs.

One therapy custom-built for a single blood cancer. Another for a single solid tumor. A third that only works after weeks of personalized cell engineering.

Meanwhile, patients wait, clinics jam up, and costs explode.

But what if one platform could be retargeted across multiple cancers—without bespoke, patient-by-patient manufacturing?

Even better…

What if that platform could scale like software — built once, then rapidly re-aimed at new tumor targets and rolled out across community clinics?

That’s exactly what this company’s TriKE platform is engineered to do.

TriKEs (Tri-specific NK cell Engagers) are off-the-shelf fusion proteins that:

Lock NK cells onto tumors via a high-affinity CD16 “grabber,”
Deliver IL-15 as built-in fuel so those NK cells multiply and persist, and
Swap targeting domains to go after multiple cancers—from CD33 (AML/MDS) to B7-H3 (solid tumors) and beyond.

If that seems like Greek to you, I’ll break it down for you: Same core scaffold. New “aiming piece.” One platform, many cancers. Infused from inventory, with no weeks-long, patient-specific cell manufacturing. Designed for real clinic workflows and broad scale.

And that’s why I have referred to it as “the Nvidia of immuno-oncology.”

Like Nvidia shipped a common compute engine that every AI team could build on, GT Biopharma’s TriKE® engine is designed to be a common immune-engagement layer teams can rapidly retarget, turning the body’s Natural Killer cells into a “Cancer Hunter” across indications.

It’s a platform built to break the two biggest bottlenecks in oncology: scale and cost.

Merck, Bristol, and the DoD All Want In On Tech Like This — Here’s Why

Right now, the latest Big Pharma arms race isn’t about one-off drugs — it’s about chasing scalable platforms.

Merck, Bristol Myers, Gilead, Sanofi, and Roche have all written multi-billion-dollar checks to secure immunotherapy engines they can deploy across multiple cancers.

Hospitals and insurers want the same thing for a different reason: off-the-shelf therapies that fit standard infusion workflows and push total episode costs toward antibody-like economics.

And the U.S. Department of Defense, through its Congressionally Directed Medical Research Programs, has consistently funded immune‑based cancer research, especially projects aimed at bridging lab discoveries into clinical or near‑clinical settings.

Their grant programs favor translational platforms that can scale, and they have supported modular immune cell engineering approaches.

That makes them a natural supporter of therapies that could move from a deployed environment (e.g. field hospital) to VA clinics … especially if they avoid fully bespoke, patient‑by‑patient manufacturing.

What ties all of this together is the platform thesis:

Build once, retarget often: one immune-engagement scaffold you can re-aim at new tumor targets.

Stock it, not custom-make it: dose from inventory, not a one-patient batch.

Scale in the real world: community-clinic delivery, predictable logistics, budgetable costs.

That’s precisely where this company’s TriKE platform lives: a modular NK-cell engager built to lock Natural Killer cells onto tumors, fuel them with IL-15, and swap the targeting domain to pursue multiple cancers from the same core design.

It’s why Fortune 500 megacaps, payers, and federal programs all care about platforms, not pills.

And it’s why over the last 18 months, the world’s largest pharmaceutical companies have been doing something very odd…

They’re not buying miracle drugs.

They’re not chasing vaccines.

They’re buying platforms — just like the one engineered by my #1 subscriber pick in the biotech sector — to use as oncology engines that can be retargeted, scaled, and deployed like plug-and-play biotech weaponry

How Big Pharma’s M&A Activity Could Turn Into a Small Cap Biotech Buyout Frenzy

Sometimes a solid investment thesis is disarmingly simple: Just follow the money.

Because when Wall Street’s fattest checkbooks start cutting billion-dollar deals in the same exact direction …You don’t debate it, you ride it.

For example, in the last few years …

Pfizer dropped $43 billion on Seagen … not for a single blockbuster drug, but for its modular ADC platform.

Merck just put $22 billion into Daiichi Sankyo … chasing a multi-asset cancer chassis built for combo treatments.

Bristol Myers shelled out $5 billion for Mirati … precision oncology with natural synergy to immune therapies.

Gilead didn’t stop at one deal. They bought Kite for $11.9 billion and Immunomedics for $21 billion, betting on cell therapy and ADC, the two hottest pairing platforms in immuno-oncology.

Even Regeneron paid nearly $1 billion upfront for full rights to a PD-1 backbone they can combine with other agents.

And Amgen? They just got the FDA’s blessing to commercialise their first T-cell engager — a major signal that this class of drugs has officially gone mainstream.

Translation: The most powerful players in global pharma are abandoning the one-drug, one-indication model and are moving into scalable, retargetable, platform-based oncology …

… Exactly where my subscriber pick lives.

I’ll reveal the company’s ticker in a moment, but first I want to reiterate what makes their platform so attractive in a time where Big Pharma is tossing around billions of dollars.

This company’s TriKE platform doesn’t just hit one cancer target.

It’s a modular immune-engager engine, engineered to be re-armed, re-aimed, and redeployed across a swath of tumours.

This is powerful IP, birthed at a top-tier academic lab, forged under the guidance of NK-cell pioneers at the University of Minnesota, and now controlled exclusively by this company.

It’s an institution-backed, biologically validated architecture, designed from Day One to be clinically relevant and commercially scalable.

And the leadership is world-class — an executive team and board filled with seasoned biotech operators, NK-cell authorities, and ex-pharma rainmakers who know how to open trial sites, run clean datasets, and strike billion-dollar partnerships with the Pfizer class.

Five Reasons GT Biopharma (NASDAQ: GTBP) Could Be the Most Asymmetric Opportunity in Biotech Today

Reason #1: Patent-Protected, Breakthrough Therapy Teaches the Body to “Seek and Destroy” Cancer Cells Naturally

GT Biopharma (NASDAQ: GTBP) has developed what could be one of the most transformative oncology platforms of the century — a patent-protected immune technology insiders are calling the “Cancer Hunter.”

Unlike traditional therapies that bombard the body with toxins or require expensive, patient-specific genetic engineering, GT Biopharma’s approach works with nature’s own frontline defenders — Natural Killer (NK) cells — and upgrades them into programmable, tumor-seeking assassins.

The company’s technology, known as TriKE (Tri-Specific Killer Engager), is already proving its power in human trials.

TriKE molecules are small fusion proteins that link NK cells directly to cancer cells, supply them with built-in fuel, and instruct them to attack relentlessly until the tumor is destroyed.

In early human studies, the company’s first-generation TriKE achieved something most biotech investors only dream of seeing: a 63.7% reduction in bone marrow blast levels. And the only reported side effect was a mild fever (easily treated with Tylenol).

That’s not an incremental improvement — it’s a leap. Most approved oncology drugs are considered successful if they show a 20%–30% response rate with tolerable toxicity.

GT Biopharma’s platform not only exceeded those expectations but did so safely, which suggests something extraordinary: the technology may finally have cracked one of oncology’s toughest challenges — how to make cell-based therapies both effective and safe.

Now, the company’s second-generation candidate, GTB-3650, is in human clinical trials targeting acute myeloid leukemia (AML) and myelodysplastic syndromes (MDS) — two of the most aggressive and deadly blood cancers known.

But here’s what’s truly disruptive: the same TriKE backbone that powers GTB-3650 can be re-targeted to attack an entirely different cancer simply by swapping out its tumor-binding domain.

In practical terms, that means the company doesn’t have to start from scratch every time it develops a new therapy. A single core design can yield multiple cancer treatments.

That’s a massive advantage.

Every new therapy becomes faster to develop, cheaper to produce, and easier to scale. And each success reinforces the value of the entire platform.

GT Biopharma’s preliminary results are showing quite a lot of promise, with an October 8 press release stating:

The Company is well on track with Phase 1 enrollment now that both patients in Cohort 3 have successfully initiated treatment with no evidence of dose-limiting toxicities or tolerability concerns to date

The first patient in Cohort 3 has shown promising evidence of immune activation consistent with levels of activity observed in patients from the previous two lower-dose cohorts; additional update anticipated by year-end.

With preliminary results like these and a scalable, protected immune-engineering platform, GT Biopharma could potentially redefine how cancer is treated for decades to come.

Its TriKE technology is a repeatable, upgradeable platform that can spawn a generation of targeted cancer therapies.

With patents covering its structure, mechanism, and manufacturing, GT Biopharma (NASDAQ: GTBP) holds the keys to a cancer fighting engine with the potential to send the company’s revenue and profits soaring.

I am telling my subscribers that means ground-floor exposure to what could become the next pillar of modern immunotherapy.

Of course, revolutionary technology means little if it can’t be deployed efficiently. The next question investors must ask is simple: can this innovation scale fast enough to meet global demand?

TriKE in action — NK cells locking onto and destroying cancer cells

Reason #2: A Scalable Solution That Cuts Costs and Multiplies Revenue Streams

The global oncology market is choking on its own complexity.

Every new therapy comes with bespoke manufacturing, complex logistics, and six-figure price tags that make them nearly impossible to scale.

CAR-T therapies, often considered the gold standard of cancer treatment, often require a patient’s own cells to be extracted, genetically modified, and reinfused. This process can take weeks and cost upwards of $750,000 per patient.

Meanwhile, cancer incidence continues to rise, particularly among aging populations. Hospitals can’t build capacity fast enough, and insurers can’t sustain the cost.

The system is under immense pressure to find therapies that deliver better results faster and cheaper.

That’s where GT Biopharma’s TriKE platform has the potential to change everything.

Each TriKE molecule is a compact, off-the-shelf fusion protein that includes three functional parts:

A binder that grabs NK cells and locks them onto cancer cells.
An agent that fuels NK cell persistence and proliferation inside the body.
A targeting arm that can be swapped out to hit specific tumor markers.

That modular design eliminates the two biggest constraints in oncology: manufacturing time and cost.

Instead of custom-engineering cells for each patient, TriKEs are manufactured like conventional biologics — scalable, consistent, and ready for clinical use.

For the FDA, this model means faster review cycles and easier reproducibility.

For hospitals, it means shelf-stable, inventory-ready therapies.

For investors, it means a business model that can generate multiple revenue streams from one technology base.

In effect, GT Biopharma’s TriKE design turns cancer therapy from a bespoke craft into an industrial science, the same way Intel turned computing into a scalable business or NVIDIA created a single architecture to power countless applications.

Each new TriKE variant built on the same backbone is a new potential drug — and a new potential royalty or acquisition target.

The speed, simplicity, and adaptability of that design is what makes this story unlike anything else in small-cap biotech today.

By building a platform that’s cheaper to produce, easier to modify, and faster to deploy, the company is positioning itself as the go-to solution for Big Pharma’s next generation of immunotherapies.

Investors who get in early aren’t just buying one drug — they’re buying a pipeline that can expand on command.

And if you’re wondering whether Big Pharma is paying attention to technologies like this — history already tells us how this story could end.

Reason #3: A Proven Blueprint With Billion-Dollar Payoffs

Every time a small company builds a proven, platform-based biotech engine, Big Pharma pounces.

When Gilead acquired Kite Pharma for $11.9 billion, it bought a single CAR-T therapy for blood cancers.

When Celgene snapped up Juno Therapeutics for $9 billion, it paid for a promising but early-stage immunotherapy pipeline.

And when Pfizer dropped $43 billion on Seagen, it wasn’t buying one drug — it was acquiring a delivery platform that could be reused across multiple cancer types.

In every case, the acquisition target had one thing in common: a validated platform that could be used again and again to generate new treatments.

GT Biopharma’s TriKE architecture follows that same model, but with key advantages that make it potentially more valuable than its predecessors.

First, TriKEs don’t require patient-specific cell manipulation, meaning they can be mass-produced and shipped to hospitals just like traditional biologics.

Second, the built-in IL-15 fuel source addresses one of cell therapy’s biggest problems: limited persistence.

TriKE-activated NK cells don’t just attack — they replicate and sustain themselves, producing longer-lasting anti-tumor activity without the life-threatening cytokine storms that derailed earlier approaches.

Third, the platform’s modular targeting domain can help keep it relevant and useful far into the future. As new tumor antigens are discovered, GT Biopharma (NASDAQ: GTBP) can simply “swap out” the targeting module and re-enter trials for new indications at a fraction of the time and cost.

Big Pharma knows exactly how to value assets like this — and the precedent numbers are staggering.

GT Biopharma (NASDAQ: GTBP), by contrast, trades at a market capitalization of roughly $3 million.

Wall Street has repeatedly shown how it rewards platform-based oncology breakthroughs. GT Biopharma’s TriKE system checks every box: validated mechanism, scalable manufacturing, modular expansion, and clean safety data.

If GTB-3650 delivers positive readouts, the revaluation potential could be staggering.

But the kind of exponential price movement I expect doesn’t happen in isolation.

It happens when powerful macro trends — demographics, regulation, and capital flow — line up behind the story.

Reason #4: RFK Jr.’s “Unleash Innovation” Mandate and the Biotech Supercycle

We’ve already briefly discussed some of the macro trends converging to push biotech out of the doldrums and into the stratosphere:

Demographics. The “silver tsunami” of aging Baby Boomers is creating historic demand for cancer care. By 2040, one in five Americans will be over 65 — the age bracket responsible for nearly 70% of cancer deaths.
Regulation. The post–Operation Warp Speed framework has shortened clinical timelines. The FDA now has fast-track precedents and adaptive trial models that make it easier than ever for proven therapies to reach patients.
Capital Rotation. Institutional investors are pivoting back to small-cap biotech after two years of overexposure to AI and tech. The NASDAQ Biotech Index has begun to show early signs of renewed inflows — typically the leading indicator for multi-year bull runs.

GT Biopharma (NASDAQ: GTBP) stands at the crossroads of these tailwinds.

It’s an American company with a patented oncology platform, operating in a sector that’s being structurally repriced.

The expected timing of its upcoming clinical milestones align perfectly with the market’s shift back toward fundamental biotech stories.

If GTB-3650 confirms early efficacy in AML and MDS, it could de-risk the entire TriKE platform and unlock a pipeline of follow-on assets ready for partnerships or licensing.

I always tell my subscribers that momentum matters as much as technology … and GT Biopharma (NASDAQ: GTBP) sits on the verge of an industry-wide inflection point.

As capital rotates back into early-stage innovation and demographic demand accelerates, this company’s story aligns perfectly with the macro setup for the next biotech supercycle.

For investors, that’s rare — and potentially life-changing.

But while the science and timing create the setup, no breakthrough scales without the right people steering it.

That’s where GT Biopharma’s leadership gives the story its final edge.

Reason #5: The Leadership Trifecta With a Track Record of Delivering Massive Wins

You’ve probably never heard of Michael Breen.

But this soft-spoken Brit, who formerly managed one of Europe’s elite private banks, now finds himself at the center of a biotech revolution that I believe could mint a new generation of biotech millionaires.

Insiders call him “The Boardroom Banker” — a solicitor by training … a former senior equity partner at legal powerhouse Clyde & Co … and a financial architect trusted by billionaires to manage their estates, inheritance schemes, and global wealth.

But Breen walked away from the world of luxury finance and turned his full attention to a little-known cancer-fighting platform …

Why?

Because what Breen discovered buried in a research lab in Minnesota could change the trajectory of cancer therapy forever

I’ve met with Breen, and spoken with him at length.

And, I have to tell you, this is a man who understands how the world really works.

He’s a legal sharp-shooter with a Rolodex of insiders, and I believe he’s about to turn this overlooked cancer startup into a weaponized cash machine.

But here’s where it gets more interesting…

While Breen handles the politics, the partnerships, and (potentially) the billion-dollar buyout negotiations …

He’s backed by a man referred to in cancer research circles as a leading “translator” of NK cell biology into clinical therapies.

His name is Dr. Jeffrey S. Miller, and he’s one of the longest-standing pioneers in Natural Killer (NK) cell therapy.

You couldn’t ask for a more powerful CV than Dr. Miller’s:

30+ years of clinical research
170+ peer-reviewed publications
Faculty at the University of Minnesota since 1991
Interim Director of the Masonic Cancer Center

As you can see from his CV, Dr. Miller has spent his career building the exact immune platform now being commercialized by GT Biopharma.

He’s secured NIH/NCI funding and led translational NK cell research for decades …

… he was among the first to show that adoptively transferred donor NK cells can persist in patients …

… and his work on NK‑based immunotherapies (including TriKEs and iPSC‑derived NKs) underpins many of today’s next‑generation cancer strategies.

In short: if you want to understand why GT Biopharma could deliver the next $5 billion cancer breakthrough … you start with Dr. Miller.

But even the best ideas can wither on the vine without the right financial engineer behind them.

Which is where Alan Urban comes in.

Urban isn’t necessarily flashy.

But if you’ve ever made money off a small-cap turnaround story … there’s a chance you’ve followed one of his deals.

He was the CFO of Research Solutions (RSSS) for 10 straight years, guiding it from obscurity into NASDAQ-listing territory.

He’s led turnarounds, tech exits, SaaS restructurings and market uplistings.

There are a lot of biotech CFOs who know how to raise a few million dollars, but Alan Urban knows how to build capital pipelines that fund billion-dollar exits.

He’s the kind of guy hedge funds like to see in the room.

He speaks their language. He knows what metrics matter. And he’s engineered shareholder returns in sectors most analysts don’t even understand.

Together, Breen, Miller, and Urban represent a rare synthesis of innovation, execution, and market strategy.

They understand both the science that drives the data and the financial architecture that converts data into shareholder value.

In biotech, management is a force multiplier. GT Biopharma’s leadership combines deep clinical credibility with the financial and legal sophistication to capture full value from its discoveries.

In my opinion, that alignment — between science, business, and execution — gives this small-cap company the DNA of a future industry leader.

Put together, these five reasons form a single, powerful thesis — a small American biotech with world-class science, clear macro tailwinds, and the right team in place is sitting at the threshold of what could be the most lucrative phase in its history.

Unlock my full research briefing on GT Biopharma, clinical timelines, and why this “Cancer Kill Switch” platform is attracting attention from Wall Street and Big Pharma.

The Bottom Line

GT Biopharma’s story reads like the blueprint for a once-in-a-decade biotech breakout.

The company owns a validated immunotherapy platform that’s modular, patent-protected, and scalable, built to attack multiple cancers while slashing cost and complexity.

It’s operating in a market where demographic inevitability guarantees rising demand and where Big Pharma is aggressively acquiring precisely this kind of technology.

Its leadership team includes one of the most respected NK-cell researchers in the world, a seasoned legal-financial strategist, and a CFO with a track record of turning small-cap innovators into major market players.

And its valuation? Barely $3 million.

If GTB-3650’s next clinical milestone delivers on even a fraction of the early promise, the revaluation potential could be immense.

GT Biopharma (NASDAQ: GTBP) represents the rarest kind of setup in investing: cutting-edge science with asymmetric upside, proven leadership, and massive macro momentum.

The Window Is Narrow … But the Opportunity Is Monumental

My number-one subscriber pick in the biotech sector, GT Biopharma (NASDAQ: GTBP), is no ordinary biotech firm.

It’s not chasing one-off drugs.

It’s not playing catch-up in a crowded oncology market.

It’s building the platform — the scalable, retargetable, plug-and-play immune-engagement engine that could become the backbone of cancer therapy for the next 30 years.

In my view, GT Biopharma (NASDAQ: GTBP) is to immuno-oncology what NVIDIA is to AI — the common infrastructure every major player will want a piece of.

➢ Patent-protected TriKE architecture with modular, scalable design

➢ Human trials already underway for GTB-3650 with promising signals

➢ Veteran team of biotech operators and NK-cell pioneers

➢ Strategic fit for Big Pharma’s multi-billion-dollar platform acquisition spree

➢ A market cap under $100 million (for now)

This is a unicorn company hiding in plain sight, but I don’t expect it to stay that way for long.

Because if GTB-3650 hits its next milestone …

If the TriKE platform is validated in the clinic …

If the market wakes up to what this “Cancer Hunter” can really do …

GT Biopharma (NASDAQ: GTBP) will no longer be a secret.

I believe Wall Street will significantly reprice it, Big Pharma will chase it, and early investors could see substantial returns from a position you can still open today for around a buck.

But as in all things, timing is everything, and the best time to act is before GT Biopharma (NASDAQ: GTBP) starts making headlines on the Wall Street Journal or Fox Business.

All of this is why I have been urging my subscribers to start their due diligence on GT Biopharma (NASDAQ: GTBP) immediately.

And now I invite you to join them.

Claim Your Share of the Potentially Enormous Profits to Be Had From America’s Biotech Revolution

I’ve spent months digging into this story… and for my money, this is one of the most compelling investment setups I’ve seen in years.

It checks all the boxes…

You’ve got a tiny, U.S.-based biotech trading at a market cap of around $3 million — I believe a fraction of its true potential.
You’ve got a patent-protected platform that can be re-aimed at multiple cancers from a single molecular design.
You’ve got early human data showing significant tumor reduction with no reported side effects — a result that rivals therapies costing hundreds of thousands of dollars.
You’ve got a leadership team stacked with Wall Street veterans and world-class cancer researchers.
And you’ve got regulatory tailwinds and demographic demand converging to create one of the biggest biotech profit waves in a generation.

It all leads me to one conclusion:

GT Biopharma Has My Five-Star Rating

Of course, nothing in the markets is guaranteed and all investments carry a degree of risk. GT Biopharma (NASDAQ: GTBP) is no exception.

While the company is gaining momentum, it’s still early in its development curve.

Which is why, as with all high-upside investments, I encourage you to move smartly — only risk capital you can afford to lose, and always do your due diligence.

To help you take the first step, I’ve written a Special Report titled The Cancer Hunter: How One Tiny Company Could Lead the Next Biotech Boom.

And it’s yours for free just by signing up below.

I encourage you — don’t wait to get your free Special Report on GT Biopharma (NASDAQ: GTBP)

Because here’s the thing most investors don’t realize until it’s too late:

The biggest wealth opportunities in biotech don’t happen after Wall Street figures it out — they happen before.

Right now, GT Biopharma (NASDAQ: GTBP) is flying completely under the radar.

It’s not on Fox Business. It’s not on the Wall Street Journal. It’s not in Barron’s … yet.

But when the next data release hits… and when the first licensing partner or institutional investor takes a position… this could go from an obscure micro-cap to the next name every biotech desk in America is talking about.

That’s why I’m urging you to get all the facts before that moment arrives.

I’ve compiled everything you need to know — including my full research notes, background on the TriKE platform, the leadership team’s history, and a detailed roadmap of upcoming catalysts — inside The Cancer Hunter: How One Tiny Company Could Lead the Next Biotech Boom.

This Special Report is designed to give you a deeper, unfiltered look into the opportunity — the kind of details that don’t make it into promotional headlines.

Inside, you’ll discover:

The full scientific story behind GT Biopharma’s TriKE platform — explained in plain English, so you can understand why Big Pharma is circling this space.
Key milestones and catalysts to watch, including the exact clinical timelines I’m tracking and what each could mean for valuation.
How to interpret early trial data like a pro — and what signals typically precede a major institutional re-rating.
Why the company’s patent portfolio matters far more than most investors realize, and how it creates what I call a “process fortress” around the entire TriKE ecosystem.
Historical comps — including what past oncology platform buyouts have paid per molecule, per patent, and per trial phase, so you can benchmark realistic upside.

This isn’t a recycled promo deck or a cookie-cutter analyst note. It’s the culmination of months of deep research — the same kind of work institutional analysts charge thousands for — distilled into one easy-to-read report you can download free.

All you need to do is enter your information below, and I’ll send you an instant link to access The Cancer Hunter: How One Tiny Company Could Lead the Next Biotech Boom.

I believe this is the kind of asymmetric setup that turns modest stakes into serious money — if you act before the crowd.

Because once Wall Street finally wakes up to the scope of this breakthrough… the biggest gains will already be in someone else’s account.

Don’t miss your chance to get positioned first.

Download your free Special Report now — and get the full story on GT Biopharma before the next phase of America’s biotech revolution begins.

To your wealth,

Jason Williams
Editor, Future Giants

IMPORTANT NOTICE AND DISCLAIMER: All investments are subject to risk, which must be considered on an individual basis before making any investment decision. This paid advertisement includes a stock profile of GT Biopharma, Inc. (Nasdaq: GTBP). Future Giants is an investment newsletter being advertised herein. This paid advertisement is intended solely for information and educational purposes and is not to be construed under any circumstances as an offer to sell or a solicitation of an offer to purchase any securities. In an effort to enhance public awareness, GT Biopharma, Inc. (Nasdaq: GTBP) is the sole source of funds for a budget of approximately $3,335,724 provided to the advertising agency to cover the costs associated with creating, printing and distribution of this advertisement. Future Giants may receive subscription revenue in the future from new subscribers as a result of this advertisement for its newsletter. The advertising agency will retain any excess sums after all expenses are paid. While this advertisement is being disseminated and for a period of not less than 90 days thereafter, Future Giants, the advertising agency, and their respective officers, principals, or affiliates will not sell securities of GT Biopharma, Inc. (Nasdaq: GTBP). If successful, this advertisement will increase investor and market awareness of GT Biopharma, Inc. (Nasdaq: GTBP) and its securities, which may result in an increased number of shareholders owning and trading the securities, increased trading volume, and possibly an increase in share price, which may be temporary. This advertisement, the advertising agency and Future Giants do not purport to provide a complete analysis of GT Biopharma, Inc. (Nasdaq: GTBP) or its financial position. They are not, and do not purport to be, broker-dealers or registered investment advisors. This advertisement is not, and should not be construed to be, personalized investment advice directed to or appropriate for any particular investor. Any investment should be made only after consulting a registered broker-dealer or registered investment advisor or, at a minimum, doing your own research if you do not utilize an investment professional to make decisions on what securities to buy and sell, and only after reviewing the financial statements and other pertinent publicly-available information about GT Biopharma, Inc. (Nasdaq: GTBP). Further, readers are specifically urged to read and carefully consider the Risk Factors identified and discussed in GT Biopharma, Inc. (Nasdaq: GTBP) SEC filings. Investing in microcap securities such as GT Biopharma, Inc. (Nasdaq: GTBP) is speculative and carries a high degree of risk. Past performance does not guarantee future results. This advertisement is based exclusively on information generally available to the public and does not contain any material, non-public information. The information on which it is based is believed to be reliable. Nevertheless, the advertising agency and Future Giants cannot guarantee the accuracy or completeness of the information and are not responsible for any errors or omissions. This advertisement contains forward-looking statements, including statements regarding expected continual growth of GT Biopharma, Inc. (Nasdaq: GTBP) and/or its industry. The advertising agency and Future Giants note that statements contained herein that look forward in time, which include everything other than historical information, involve risks and uncertainties that may affect GT Biopharma, Inc. (Nasdaq: GTBP) actual results of operations. Factors that could cause actual results to vary include the size and growth of the market for GT Biopharma, Inc. (Nasdaq: GTBP) products and/or services, the company’s ability to fund its capital requirements in the near term and long term, federal and state regulatory issues, pricing pressures, etc. Future Giants is the publisher’s trademark. All trademarks used in this advertisement other than Future Giants are the property of their respective trademark holders and no endorsement by such owners of the contents of this advertisement is made or implied. The advertising agency and Future Giants are not affiliated, connected, or associated with, and are not sponsored, approved, or originated by, the trademark holders unless otherwise stated. No claim is made to any rights in any third-party trademarks.